Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 262

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza: A Randomized Trial

Wang, Chen, Cao, Bin, Liu, Qing-Quan, Zou, Zhi-Qiang, Liang, Zong-An, Gu, Li, Dong, Jian-Ping, Liang, Li-Rong, Li, Xing-Wang, Hu, Ke, He, Xue-Song, Sun, Yan-Hua, An, Yu, Yang, Ting, Cao, Zhi-Xin, Guo, Yan-Mei, Wen, Xian-Min, Wang, Yu-Guang, Liu, Ya-Ling, Jiang, Liang-Duo · 2011 · Annals of Internal Medicine

Abstract

BACKGROUND: Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. OBJECTIVE: To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza. DESIGN: Prospective, nonblinded, randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00935194) SETTING: Eleven hospitals from 4 provinces in China. PATIENTS: 410 persons [corrected] aged 15 to 69 [corrected] years with laboratory-confirmed H1N1 influenza. INTERVENTION: Oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; or no intervention (control). Interventions and control were given for 5 days. MEASUREMENTS: Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction. RESULTS: Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan-yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan-yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P = 0.05) with oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P = 0.38). Two patients who received maxingshigan-yinqiaosan reported nausea and vomiting. LIMITATIONS: Participants were young and had mild H1N1 influenza virus infection. Missing viral data precluded definitive conclusions about viral shedding. CONCLUSION: Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection. PRIMARY FUNDING SOURCE: Beijing Science and Technology Project and Beijing Nova Program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-155-4-201108160-00005

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 262

Metadata

Authors
Wang, C., Cao, B., Liu, Q.-Q., Zou, Z.-Q., Liang, Z.-A., Gu, L., Dong, J.-P., Liang, L.-R., Li, X.-W., Hu, K., He, X.-S., Sun, Y.-H., An, Y., Yang, T., Cao, Z.-X., Guo, Y.-M., Wen, X.-M., Wang, Y.-G., Liu, Y.-L., & Jiang, L.-D.
Venue
Annals of Internal Medicine
Published
2011-08-16
Volume
155
Issue
4
Pages
217-225
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2010581642
Cited by
262
References
20
FWCI
9.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-155-4-201108160-00005
The paper
Wang, C., Cao, B., Liu, Q.-Q., Zou, Z.-Q., Liang, Z.-A., Gu, L., Dong, J.-P., Liang, L.-R., Li, X.-W., Hu, K., He, X.-S., Sun, Y.-H., An, Y., Yang, T., Cao, Z.-X., Guo, Y.-M., Wen, X.-M., Wang, Y.-G., Liu, Y.-L., & Jiang, L.-D. (2011). Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-155-4-201108160-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.